Tech Center 1600 • Art Units: 1636 1637 1699
This examiner grants 52% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18146818 | COMPOSITION FOR PREVENTING OR TREATING ALZHEIMER'S DISEASE COMPRISING INHIBITOR OF ATLASTIN 2, AND METHOD FOR DIAGNOSING ALZHEIMER'S DISEASE BY DETERMINING ATLASTIN 2 | Non-Final OA | Research & Business Foundation Sungkyunkwan University |
| 17600984 | METHODS OF TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH INCREASED TET LEVEL, INCREASED H19 LEVEL, INCREASED LEVEL OF TGF SIGNALING, OR ANY COMBINATION THEREOF | Final Rejection | YALE UNIVERSITY |
| 17602076 | Enhancement of Melanocyte Migration Using ROCK Inhibitors | Non-Final OA | The General Hospital Corporation |
| 17595703 | TREATMENT AGENT FOR SEX HORMONE-INSENSITIVE GREB1-POSITIVE TUMORS | Non-Final OA | OSAKA UNIVERSITY |
| 18275634 | Methods of Protecting RNA | Non-Final OA | Pfizer Inc. |
| 17635363 | COMBINATION THERAPY FOR SPINAL MUSCULAR ATROPHY | Non-Final OA | Biogen MA Inc. |
| 18385005 | COMPOSITIONS AND METHODS FOR TREATING TRANSTHYRETIN (TTR) MEDIATED AMYLOIDOSIS | Non-Final OA | Alnylam Pharmaceuticals, Inc. |
| 17438920 | MODIFYING THE SPECIFICITY OF NON-CODING RNA MOLECULES FOR SILENCING GENES IN EUKARYOTIC CELLS | Final Rejection | Tropic Biosciences UK Limited |
| 17287563 | METHOD FOR SUPPRESSING PROTEIN TRANSLATION REACTION USING STAPLE NUCLEIC ACID | Non-Final OA | HIROSAKI UNIVERSITY |
| 18552778 | EXTRACELLULAR VESICLE COMPOSITIONS | Non-Final OA | LONZA SALES AG |
| 17291922 | An lncRNA integrates a DNA-PK-mediated DNA damage response and vascular senescence | Non-Final OA | The Brigham and Women`s Hospital, Inc. |
| 18272699 | SEQUENTIAL DELIVERY OF RNPS TO IMMUNE CELLS | Non-Final OA | Avectas Limited |
| 17299275 | METHODS FOR THE TREATMENT OF TRINUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH OGG1 ACTIVITY | Non-Final OA | TAKEDA PHARMACEUTICALS U.S.A., INC. |
| 17997138 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR AT LEAST ONE TYPE OF CANCER SELECTED FROM GROUP CONSISTING OF PANCREATIC CANCER, LUNG CANCER, COLORECTAL CANCER, CHOLANGIOCARCINOMA AND LIVER CANCER, PROPHYLACTIC OR THERAPEUTIC AGENT FOR SAID CANCER WHICH IS USED IN COMBINATION DRUG IN COMBINATION WITH SAID AGENT, COMBINATION DRUG COMPRISING SAID AGENTS, AND METHOD FOR SCREENING FOR PROPHYLACTIC OR THERAPEUTIC AGENT FOR CANCER | Non-Final OA | TAK-CIRCULATOR CO., LTD. |
| 17915215 | Targeted Inhibition Using Engineered Oligonucleotides | Non-Final OA | miRecule, Inc. |
| 17779016 | Nucleic Acids, Vectors, Host Cells and Methods for Production of Beta-Fructofuranosidase from Aspergillus Niger | Final Rejection | Revelations Biotech Pvt Ltd |
| 17216169 | Adult Stem Cell Line Introduced with Hepatocyte Growth Factor Gene and Neurogenic Transcription Factor Gene with Basic Helix-Loop-Helix Motif and Uses Thereof | Non-Final OA | CELL&BRAIN CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy